Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, safety, efficacy trial of ANS-6637 for opioid misuse

Trial Profile

A Phase II, safety, efficacy trial of ANS-6637 for opioid misuse

Planning
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs ANS 6637 (Primary)
  • Indications Opioid abuse
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SEARCH
  • Most Recent Events

    • 25 Sep 2018 New trial record
    • 19 Sep 2018 According to an Amygdala Neurosciences media release, the project is led by Dr. Henry Masur, Chief of the NIH Critical Care Medicine Department and Dr. Shyam Kottilil (University of Maryland School of Medicine) and being conducted by the NIH Clinical Center and the Institute of Human Virology (IHV) at the University of Maryland School of Medicine.
    • 19 Sep 2018 According to an Amygdala Neurosciences media release, this trial is being conducted under The SEARCH program of clinical studies and will receive up to $12.4 million of funding from the NIH HEAL (Helping to End Addiction Long-term) initiative.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top